- Oncodesign Services has extended its collaboration with GIP ARRONAX to secure access to astatine-211 (At-211) for targeted alpha radiotherapy programs.
- The partnership aims to address supply constraints and support discovery and preclinical CRO programs in radiopharmaceutical development.
Oncodesign Services announced it has extended its collaboration with GIP ARRONAX to strengthen access to astatine-211 (At-211), a radionuclide used in targeted alpha radiotherapy. The agreement builds on an existing partnership and is intended to support discovery and preclinical CRO programs that rely on consistent access to specialized isotopes.
The collaboration focuses on securing supply of At-211, an alpha-emitting radionuclide with growing interest in oncology but limited availability due to its short half-life and complex production requirements. Ensuring reliable access is considered critical for advancing radiopharmaceutical research and enabling efficient study execution.
GIP ARRONAX, a French research institute specializing in radionuclide production, has been supplying isotopes such as lead-203 and copper-64 to Oncodesign Services. The expanded agreement now includes At-211, supporting ongoing translational and preclinical development programs. The partnership is designed to reduce supply bottlenecks and improve continuity across radiopharmaceutical studies.
From a CRO perspective, access to radionuclides like At-211 requires tight coordination across production, transport, and study timelines. The collaboration is intended to align operational logistics with scientific development, helping ensure that preclinical programs can progress without delays caused by supply limitations.
“Extending our collaboration with GIP ARRONAX helps address these constraints and supports continuity in preclinical programmes.”
Dr. Aidan Synnott, Chief Executive Officer of Oncodesign Services
Sign up to the free weekly newsletter for all the latest news, resources and podcasts in contract manufacturing. 
